Open AccessCardiovascular toxicity of contemporary antiretroviral therapy
Author(s) -
Antonie Vos,
W D Francois Venter
Publication year - 2021
Publication title -
current opinion in hiv and aids
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.901
H-Index - 64
eISSN - 1746-6318
pISSN - 1746-630X
DOI - 10.1097/coh.0000000000000702
Subject(s) - efavirenz , integrase inhibitor , stavudine , discontinuation , medicine , integrase , antiretroviral therapy , zidovudine , lipodystrophy , pharmacology , disease , intensive care medicine , human immunodeficiency virus (hiv) , viral load , virology , viral disease
HIV treatment has evolved since the introduction of antiretroviral therapy (ART) in the 1990s. Earlier treatment strategies, and the introduction of integrase inhibitors in preferred first-line ART have fundamentally changed cardiovascular side effects due to HIV infection and ART. This review provides an update on cardiovascular toxicity of contemporary ART.